Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up  Willem P. Brouwer, Henry Lik-Yuen Chan, Maurizia R. Brunetto, Michelle Martinot-Peignoux, Pauline Arends, Markus Cornberg, Beatrice Cherubini, Alex J.V. Thompson, Yun-Fan Liaw, Patrick Marcellin, Harry L.A. Janssen, Bettina E. Hansen  Clinical Gastroenterology and Hepatology  Volume 14, Issue 10, Pages 1481-1489.e5 (October 2016) DOI: 10.1016/j.cgh.2016.01.019 Copyright © 2016 AGA Institute Terms and Conditions

Figure 1 Cumulative probability to remain IC during follow-up given HBsAg at inclusion. *HBsAg 100–1000 IU/mL versus >1000 IU/mL: HR, 0.61; 95% CI, 0.3–1.2; P = .144. Two IC patients did not have further follow-up beyond Year 1. Clinical Gastroenterology and Hepatology 2016 14, 1481-1489.e5DOI: (10.1016/j.cgh.2016.01.019) Copyright © 2016 AGA Institute Terms and Conditions

Figure 2 Probability of switching given IC (A) or HBV activity (B) and the combination of HBsAg levels in the prior year. Total number of visit-years in this analysis is n = 234 (A) and n = 131 (B). A “visit-year” is a maximum HBV phase and HBsAg level within a follow-up year and thus an umbrella term for multiple visits within a follow-up year. Clinical Gastroenterology and Hepatology 2016 14, 1481-1489.e5DOI: (10.1016/j.cgh.2016.01.019) Copyright © 2016 AGA Institute Terms and Conditions

Figure 3 Cumulative probability of HBsAg loss given baseline HBsAg levels. ∗Six patients with HBsAg ≤100 IU/mL lost HBsAg during the first follow-up year, and 26 patients did not have follow-up beyond the first year and were not included in this analysis. Clinical Gastroenterology and Hepatology 2016 14, 1481-1489.e5DOI: (10.1016/j.cgh.2016.01.019) Copyright © 2016 AGA Institute Terms and Conditions

Supplementary Figure 1 Schematic example of dynamic regression analysis using a moving timeframe. Clinical Gastroenterology and Hepatology 2016 14, 1481-1489.e5DOI: (10.1016/j.cgh.2016.01.019) Copyright © 2016 AGA Institute Terms and Conditions

Supplementary Figure 2 Mean HBsAg level decline from inclusion in inactive carriers versus patients with HBV activity. Clinical Gastroenterology and Hepatology 2016 14, 1481-1489.e5DOI: (10.1016/j.cgh.2016.01.019) Copyright © 2016 AGA Institute Terms and Conditions

Supplementary Figure 3 Predicted probability of becoming IC the next year given HBsAg decline and HBV DNA levels. Clinical Gastroenterology and Hepatology 2016 14, 1481-1489.e5DOI: (10.1016/j.cgh.2016.01.019) Copyright © 2016 AGA Institute Terms and Conditions